drugset
drugset / Trial / NCT02950038

Study of Ibrutinib Followed by Ibrutinib in Combination With Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

NCT02950038 ↗

Phase 2 Withdrawn M.D. Anderson Cancer Center Janssen Scientific Affairs, LLC · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if Imbruvica (ibrutinib) alone and then in combination with Opdivo (nivolumab) can control NSCLC in patients who have received previous chemotherapy treatment.

Timeline

Start
2016-12
Primary completion
2019-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Ibrutinib Small molecule 560 mg Oral
Subject Nivolumab Monoclonal antibody 3 mg/kg Intravenous

Indications

non-small cell lung carcinoma